Consistently, in the post-primary infection group, the NT50 assessed using Vero cells with partially mature virions (OR 0.75, 95% CI 0.58–0.93) and mature virions (OR 0.79, 95% CI 0.63–0.97), as well as the NT50 assessed using Vero DC-SIGN cells with partially mature virions (OR 0.73, 95% CI 0.55–0.92) and mature virions (OR 0.31, 95% CI 0.12–0.65), were associated with lower risk of subsequent symptomatic DENV infection using our logistic regression model (Table 1). The gene discussed is CD209; the disease is infection.